Sökning: "miRNA processing"
Visar resultat 1 - 5 av 11 avhandlingar innehållade orden miRNA processing.
1. The diverse functions of the ADAR enzymes : Editing and editing-independent effects on gene expression
Sammanfattning : The adenosine deaminase acting on RNA (ADAR) family of enzymes consists of three members (ADAR1-3). These enzymes are responsible for the deamination of adenosine into inosine in double-stranded RNA, one of the most common RNA modifications in mammals. LÄS MER
2. MicroRNAs and their processing factors in Caenorhabditis elegans and human cancers
Sammanfattning : MicroRNAs (miRNAs) are small noncoding RNAs approximately 20-22 nucleotides (nt) long. These small RNAs (sRNAs) was initially discovered in Caenorhabditis elegans (C. elegans), but is conserved in over 50 animal species. LÄS MER
3. Identification of miRNA expression profiles for diagnosis and prognosis of prostate cancer
Sammanfattning : Cancer of the prostate (CaP) is the most common malignancy diagnosed in men in the Western society. During the last years, prostate specific antigen (PSA) has been used as a biomarker for CaP, although a high PSA value is not specific for CaP. Thus, there is an urgent need for new and improved diagnostic markers for CaP. LÄS MER
4. Adenoviral small non-coding RNAs : A Structural and Functional Charaterization
Sammanfattning : Since their discovery in 1953, adenoviruses have significantly contributed to the understanding of virus-host cell interactions, including mechanistic details of cellular processes such as cell cycle control and alternative RNA splicing. Among the first characterized adenoviral genes were the virus-associated RNAs (VA RNAI/II), which are produced in massive amount during a lytic infection. LÄS MER
5. MicroRNAs in HER2-Amplified Breast Cancer
Sammanfattning : Background: Breast cancer is the most common female malignancy and the leading cause of cancer-related deaths worldwide. Targeted therapy against the main biomarkers estrogen receptor alpha (ER) and human epidermal growth factor receptor 2 (HER2/ERBB2) have greatly improved mortality rates, but ab initio or acquired therapy resistance is common. LÄS MER